Drug Discovery in Japan

Dr. Sadao Nagaoka is a Professor of economics at Tokyo Keizai University (Japan). Before this position, he was a professor at the Institute of Innovation Research of Hitotsubashi University (Japan). He has been the Program Director for research on innovation in the Research Institute of Economy, Trade and Industry (RIETI). He worked in the MITI, the World Bank and in the OECD. He has been an economic advisor for the JPO and was a member of the Economic and Scientific Advisory Board of the EPO. He has a Ph.D. in Economics from Massachusetts Institute of Technology. His scientific interests are economics of innovation, especially R&D, intellectual property, standards and science. His recent publications appeared in Journal of Economics & Management Strategy, International Journal of Industrial Organization, Research Policy, Economics of Innovation and New Technology, Journal of Technology Transfer, Journal of the Japanese and International Economies and the US National Academies.

• Foreword.- Acknowledgement.- Chapter 1: Introduction.- Chapter 2: Compactin.- Chapter 3: Pravastatin (Pravachol, Mevalotin).- Chapter 4: Rosuvastatin(Crestor).- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur).- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit).- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC).- Chapter 8: Pranlukast (Onon).- Chapter 9: Tacrolimus (Prograf).- Chapter 10: Pioglitazone (Actos, Glustin).- Chapter 11: Donepezil (Aricept).- Chapter 12: Candesartan (Blopress, Atacand).- Chapter 13: Tocilizumab (Actemra,Ro-actemra).- Chapter 14: Nivolumab (Opdivo).- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.